Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. Januar 2018 08:45 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Data in the Journal of Clinical Pharmacology

MALVERN, Pa., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
03. Januar 2018 11:16 ET | Quelle: Recro Pharma, Inc.

UPDATE – Recro Pharma Announces Key Executive Promotions to the Financial Team

MALVERN, Pa., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
03. Januar 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces Key Executive Promotions to the Financial Team

MALVERN, Pa., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
29. Dezember 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Reports Inducement Grants for New Staff

MALVERN, Pa., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
20. November 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Secures $100 Million Credit Facility

Proceeds Provide Funding for IV Meloxicam 30mg Approval Milestone Interest-only Structure Allows for Reinvestment of CDMO Cash Flows in Value Accretive Commercial Activities Substantial Reduction in...
09. November 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Reports Third Quarter 2017 Financial Results

NDA Submission for IV Meloxicam Accepted by U.S. FDA for Review; PDUFA Date Set for May 26, 2018 Strong Gainesville Manufacturing Performance; Third Quarter 2017 Revenues of $17.1 Million MALVERN,...
08. November 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma to Present at Upcoming Investor Conferences

MALVERN, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
31. Oktober 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Reports Inducement Grants for New Staff

MALVERN, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
10. Oktober 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting

IV Meloxicam 30mg Demonstrates Statistically Significant Reductions in Pain, Along with Reductions in Opioid Rescue Use and Improvements in Several Other Pain Relief Metrics Selected as a “Top 6”...
05. Oktober 2017 17:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma to Participate in Upcoming Investor Conferences

MALVERN, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...

Vorherige Seite